Insulin sensitivity improvement

"Insulin sensitivity improvement" is not a specific molecule or receptor but rather a **therapeutic goal** or physiological process. It refers to increasing the responsiveness of cells—primarily in skeletal muscle, adipose tissue, and liver—to the hormone insulin. This process is central to managing conditions like type 2 diabetes, prediabetes, obesity, and related metabolic disorders. Drugs such as metformin and thiazolidinediones are used clinically to improve insulin sensitivity by enhancing cellular uptake of glucose or modulating metabolic/inflammatory pathways. However, "insulin sensitivity improvement" itself does not correspond to a single molecular target; instead, it encompasses multiple mechanisms involving various receptors (e.g., insulin receptor), enzymes, transcription factors (e.g., PPARγ), immune mediators, and metabolic regulators.[1][3][4] Therefore it should not be considered a canonical drug target. **Note:** The entry "Insulin sensitivity improvement" is conceptually incorrect as a molecular target because it describes an outcome or effect rather than a discrete protein/receptor/enzyme that can be directly targeted by drugs.[6]

Other names

Insulin sensitivity improvementImproved insulin sensitivity

- Enhancing cellular response to insulin in muscle and fat tissue[2][1] - Reducing hepatic glucose production (metformin)[2] - Modulating inflammation and adipokine signaling pathways (TZDs)[1][5]